Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-XHER2 PET/CT for HER2 Expression in Solid Tumors
NCT07885436Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-XHER2 in solid tumor, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Feasibility of PET/CT imaging with 68Ga-XHER2 for the non-invasive assessment of HER2 expression at 1 month. Started Oct 2026; status: recruiting.
02
Drugs
68Ga-XHER2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07885436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885436.